Loading...

Mark Lathrop

Home / Investigators  / Mark Lathrop

Mark Lathrop

Professor, Department of Human Genetics

Email: directoradmin.genome@mcgill.ca
Phone: (514) 398-6583

740 Dr Penfield Ave, Room 6105
Montréal, Québec, Canada, H3A 0G1

Professor Lathrop’s areas of research interest lie in the application of genomics and statistical methods to understand the molecular basis of human disease. He joined the McGill University in 2011 where he is Professor in the Department of Human Genetics and Scientific Director of the McGill Genome Centre. Dr. Lathrop was trained in theoretical statistics and genetics at the University of Washington. After obtaining his PhD, he moved to France where he was one of the founding members of the CEPH, which pioneered the international collaboration on the human genome in the 1980s and 1990s. In 1993, he moved to the University of Oxford, where he was a Wellcome Trust Principal Fellow and Professor of Human Genetics. At the University of Oxford he was the co-founder and first scientific director of the Wellcome Trust Centre for Human Genetics, an institute created to apply genomic approaches to understanding the molecular basis of human disease. At the request of the French government he returned to France in 1998 to found the centre National de Génotypage which developed into the principal national infrastructure for human genetic studies in France.. In 2005, the French government asked Pr. Lathrop to serve also as the scientific director of the Fondation Jean Dausset – Centre d’Etude du Polymorphism. He held these responsibilities until taking up his position at McGill.

Recent Publications

  • Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y et al.. Author Correction: The repertoire of mutational signatures in human cancer. Nature. 2023; :. doi: 10.1038/s41586-022-05600-5. PubMed PMID:36697836 .
  • Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K et al.. Author Correction: Patterns of somatic structural variation in human cancer genomes. Nature. 2023; :. doi: 10.1038/s41586-022-05597-x. PubMed PMID:36697835 .
  • ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Author Correction: Pan-cancer analysis of whole genomes. Nature. 2023; :. doi: 10.1038/s41586-022-05598-w. PubMed PMID:36697834 .
  • Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D et al.. Author Correction: The evolutionary history of 2,658 cancers. Nature. 2023; :. doi: 10.1038/s41586-022-05601-4. PubMed PMID:36697833 .
  • Rheinbay, E, Nielsen, MM, Abascal, F, Wala, JA, Shapira, O, Tiao, G et al.. Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2023; :. doi: 10.1038/s41586-022-05599-9. PubMed PMID:36697832 .
  • PCAWG Transcriptome Core Group, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y et al.. Author Correction: Genomic basis for RNA alterations in cancer. Nature. 2023; :. doi: 10.1038/s41586-022-05596-y. PubMed PMID:36697831 .
  • Carlevaro-Fita, J, Lanzós, A, Feuerbach, L, Hong, C, Mas-Ponte, D, Pedersen, JS et al.. Author Correction: Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 2022;5 (1):1347. doi: 10.1038/s42003-022-03769-z. PubMed PMID:36482178 PubMed Central PMC9732278.
  • Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N et al.. Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 2022;13 (1):7567. doi: 10.1038/s41467-022-32336-7. PubMed PMID:36482170 PubMed Central PMC9731941.
  • Sieverling, L, Hong, C, Koser, SD, Ginsbach, P, Kleinheinz, K, Hutter, B et al.. Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2022;13 (1):7574. doi: 10.1038/s41467-022-32328-7. PubMed PMID:36481818 PubMed Central PMC9731961.
  • Shuai, S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger, S, Stein, LD, PCAWG Consortium. Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2022;13 (1):7571. doi: 10.1038/s41467-022-32343-8. PubMed PMID:36481739 PubMed Central PMC9732291.
Search PubMed